Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).

[1]  S. Gui,et al.  Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. , 2017, World neurosurgery.

[2]  H. Gelderblom,et al.  Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series , 2016, Clinical Sarcoma Research.

[3]  C. Bettegowda,et al.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival , 2016, Neuro-oncology.

[4]  J. Blay,et al.  Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO) , 2016, Oncotarget.

[5]  Liwei Zhang,et al.  Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups. , 2016, World neurosurgery.

[6]  M. Zou,et al.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. , 2016, American journal of translational research.

[7]  Jianjun Li,et al.  PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma. , 2016, Cancer biomarkers : section A of Disease markers.

[8]  Kevin M. Curtis,et al.  Characteristics and Patterns of Metastatic Disease from Chordoma , 2015, Sarcoma.

[9]  P. Casali,et al.  Imatinib in advanced chordoma: A retrospective case series analysis. , 2015, European journal of cancer.

[10]  J. Blay,et al.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  B. Chauffert,et al.  Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. , 2015, Critical reviews in oncology/hematology.

[12]  S. Stacchiotti,et al.  Building a global consensus approach to chordoma: a position paper from the medical and patient community. , 2015, The Lancet. Oncology.

[13]  V. Rohde,et al.  Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma , 2014, European Spine Journal.

[14]  Kangwu Chen,et al.  Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis , 2014, Medical Oncology.

[15]  V. Rohde,et al.  Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients. , 2014, Anticancer research.

[16]  H. Mankin,et al.  Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma , 2013, PloS one.

[17]  L. Mariani,et al.  Phase II study on lapatinib in advanced EGFR-positive chordoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Stupp,et al.  Phase II study of imatinib in advanced chordoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Richard Simon,et al.  Evaluation of randomized discontinuation design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Kindblom,et al.  Prognostic factors in chordoma of the sacrum and mobile spine , 2000, Cancer.

[21]  H. Tawbi,et al.  Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor , 2017, Cancer.

[22]  Prise en charge de la douleur chez l’adulte , 2011, Oncologie.